The $10 Billion Wealth Evaporation
Jiang Rensheng (蒋仁生) and his son Jiang Lingfeng (蒋凌峰), founders of vaccine giant Zhifei Biological, have witnessed one of China’s most dramatic wealth collapses in recent corporate history. According to the 2025 New Wealth 500 Rich List, their combined fortune stands at 3.84 billion yuan ($530 million) – a staggering 72.24 billion yuan ($10 billion) decline from their 2022 peak of 110.66 billion yuan. This wealth erosion directly mirrors Zhifei Biological’s stock performance, with shares plummeting from their 2021 high to a current market capitalization of 56.37 billion yuan, wiping out nearly 300 billion yuan in shareholder value.
Three critical factors converged to create this perfect storm:
- Collapse in HPV vaccine demand after pandemic-era shortages eased
- Fierce price competition from domestic vaccine manufacturers
- Overdependence on Merck’s vaccine portfolio (94.6% of 2024 revenue)
Key Takeaways
- Jiang Rensheng (蒋仁生) and Jiang Lingfeng (蒋凌峰) lost 72.24B yuan ($10B) in personal wealth since 2022 as Zhifei Biological shares crashed
- Zhifei’s revenue plunged 50.7% in 2024 with net profit down 75% amid HPV vaccine market saturation
- Merck’s HPV vaccines now face brutal price wars as domestic competitors slash prices by 90%
- Leadership transition to son Jiang Lingfeng (蒋凌峰) failed to reverse losses: Q1 2025 saw 305M yuan net loss
- Patent expiries and 19 new pipeline vaccines represent make-or-break challenges for recovery
From Rural Teacher to Vaccine Billionaire
Jiang Rensheng’s (蒋仁生) journey to wealth was as improbable as its collapse. Born in 1953 in rural Guangxi, he taught at a village primary school after high school before entering Guilin Medical College (now Guilin Medical University). His nearly two-decade tenure in Guangxi’s disease prevention system laid the groundwork for his vaccine empire.
The Pivotal Career Gamble
In 1999, the 46-year-old Jiang shocked colleagues by abandoning his “iron rice bowl” position at Nanning Health and Epidemic Prevention Station to join a Chengdu vaccine distributor. This daring move culminated in June 2002 when Jiang partnered with Liu Junhui (刘俊辉) and Wu Guanjiang (吴冠江) to acquire Chongqing Jinxin Biological Products, later renamed Chongqing Zhifei Biological Products.
The company’s breakthrough came through exclusive distribution rights for the AC meningococcal polysaccharide vaccine. Early success couldn’t prevent a schism: Liu Junhui (刘俊辉) departed in 2007 over strategic differences (later co-founding Walvax Biotech), while Wu Guanjiang (吴冠江) remained as a major shareholder.
The Merck Partnership That Built an Empire
Zhifei’s 2010 IPO paved the way for transformative deals with Merck:
- 2012: Secured exclusive rights to distribute 4-valent HPV vaccine in China
- 2018: Added 9-valent HPV vaccine distribution rights
These agreements propelled astronomical growth:
- Revenue skyrocketed from 446M yuan (2016) to 52.9B yuan (2023)
- Net profit exploded from 32.5M yuan to 8.07B yuan over same period
- Market valuation peaked near 350B yuan, crowning Jiang Rensheng (蒋仁生) as Chongqing’s richest person
The HPV Vaccine Collapse
Zhifei’s golden goose became its greatest vulnerability. By 2024, Merck’s HPV vaccines accounted for 94.6% of Zhifei’s 26.07B yuan revenue – but that revenue stream was evaporating.
Market Dynamics Turned Toxic
Four structural shifts destroyed Zhifei’s profitable vaccine monopoly:
- 9-valent HPV production increased 47% year-over-year through 2023
- China expanded vaccination age limits to 9-45 year olds (from 16-26)
- Domestic 2-valent alternatives entered market at 90% discounts
- Vaccine hesitancy surged post-pandemic
The impact was catastrophic for Zhifei:
- 4-valent HPV shipments collapsed 95.5% in 2024
- 9-valent HPV doses declined 14.8% despite expanded eligibility
- Rotavirus vaccine shipments fell 23.2%
Price Wars Erupt
Competition turned brutal in 2024 when Walvax Biotech slashed 2-valent HPV prices to 27.5 yuan/dose – lower than bubble tea. This triggered industry-wide repricing:
- Zhifei cut 23-valent pneumonia vaccine prices 30% to 209 yuan
- Merck’s HPV vaccines now face 60-80% premium erosion
The timing couldn’t be worse: Merck’s 9-valent HPV patents expire in 2025, opening floodgates to domestic competitors. Three Chinese manufacturers already have late-stage candidates:
- Wantai Biological’s application under review since August 2024
- CanSino’s candidate entering Phase III trials
- KangLe Guardian completing Phase III analysis in February 2025
Leadership Crisis
As losses mounted in September 2024, 72-year-old Jiang Rensheng (蒋仁生) initiated China’s most scrutinized biotech succession plan. He elevated son Jiang Lingfeng (蒋凌峰) to Vice Chairman and CEO, relinquishing the latter role after 16 years.
The Reluctant Successor
Jiang Lingfeng’s (蒋凌峰) path to leadership was unconventional. After graduating from Guangxi University’s law school, the 1980-born heir worked briefly at Guangxi’s Binxian County Tobacco Bureau before joining Zhifei in 2004. Colleagues describe him as low-key, with Jiang Rensheng (蒋仁生) publicly praising his “practical character and strong capabilities.”
His leadership baptism proved brutal:
- 2024 revenue fell 50.7% year-over-year
- Net profit plunged 74.99% to 2.02B yuan
- Q1 2025 losses hit 305M yuan on 79.2% revenue decline
Strategic Missteps
Analysts cite three critical errors during the transition:
- Overestimating GSK’s shingles vaccine impact (377,600 doses in 2024)
- Underinvesting in domestic R&D until competition emerged
- Failing to diversify beyond Merck as patents neared expiration
Road to Recovery
With HPV revenues in freefall, Zhifei’s survival hinges on its 1.39B yuan R&D investment. The company currently has 34 development projects, with 19 in clinical or registration phases.
Pipeline Prospects
Notable pipeline vaccines include:
- Recombinant COVID-19 vaccine (Phase III)
- Group B streptococcus vaccine (Phase I)
- Pneumococcal conjugate vaccine (Preclinical)
However, diversification faces significant hurdles:
- Average vaccine development takes 10-15 years
- New facilities require 2-3B yuan investments
- Price pressures now extend beyond HPV to pneumonia and rotavirus vaccines
Market Realities
Zhifei’s challenges reflect broader vaccine industry headwinds:
- China’s vaccine procurement prices dropped 22% industry-wide in 2024
- Inventory glut exceeds 180M surplus doses nationwide
- Vaccination rates remain 18% below pre-pandemic levels
Future Imperatives
For Zhifei Biological to reclaim its former glory, three strategic pivots are essential:
- Accelerate proprietary vaccine commercialization before 2026
- Repatriate overseas cash reserves (estimated 3.8B yuan) for R&D funding
- Pursue strategic acquisitions in mRNA or novel adjuvant technologies
Jiang Rensheng (蒋仁生) faces his greatest challenge since founding Zhifei in 2002. The company that rode the HPV vaccine boom must now reinvent itself amid perfect storm of patent cliffs, price wars, and leadership transition. With institutional investors holding just 12.7% of shares – and Jiang family controlling 51.2% – the pressure falls squarely on the founders to engineer a turnaround. The coming 18 months will determine whether this wealth collapse becomes permanent – or merely a painful chapter in Zhifei’s evolution.
What’s Next: Track Zhifei Biological’s Q2 2025 earnings release on September 15 for critical updates on Merck contract renegotiations and pipeline progress. Investors should monitor patent expiry impacts on competing HPV vaccines as domestic alternatives launch.